Antifungal Drug Market Report 2025 (Global Edition)

Global Antifungal Drug Market Report 2025 Market Size Split by Drug Class (Azoles, Echinocandins, Polyenes, Allylamine, Pyrimidines, Others), by Route of Administration (Oral, Topical, Parenteral), ...

Antifungal Drug Market Report Description

We have various report editions of Antifungal Drug Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.

The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.

Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.

Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.

Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.

Competitive Landscape: The Antifungal Drugs Market

The anti-fungal treatment market is distinguished by the presence of numerous, key players catering to medical devices that are evolving at a rapid pace. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their drugs and signing contracts and agreements to broaden their reach and reduce operational costs. Moreover, the anti-fungal treatment market is extremely competitive, with players competing, partnering, and investing heavily in R&D to gain a significant market share. The market is moderately fragmented with rising competition, product launches, increasing collaborative partnerships, and other strategic decisions to achieve operational efficiency. 
For instance, in August 2023, Sandoz's acquisition of worldwide brand rights for Mycamine from Astellas showcases strategic consolidation to strengthen global hospital offerings. This aligns with industry trends, emphasizing the importance of anti-infective portfolios to meet evolving healthcare needs.
Source:(https://www.novartis.com/news/media-releases/sandoz-completes-acquisition-leading-antifungal-agent-mycamine-from-astellas-reinforcing-leading-global-anti-infectives-portfolio)

 

Top Companies Market Share in Antifungal Drug Industry: (In no particular order of Rank)

• Pfizer Inc
• Johnson & Johnson Services
• Inc
• Bayer AG
• Novartis AG
• Abbott Laboratories
• Inc.
• Merck & Co.
• Inc.
• Gilead Sciences
• Inc
• Cipla
• Inc.
• Sanofi S.A.
• GlaxoSmithKline Plc
• Glenmark
• Enzon Pharmaceuticals
• Inc.
• Astellas Pharma
• Inc.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of The Antifungal Drugs Market

Which Region Will Dominate the Market in 2024?

According to Cognitive Research, the North American region dominated the Antifungal Drugs market and accounted for the highest revenue of XX% in 2024 and it is projected that it will grow at a CAGR of XX% in the future. In North America, Fungal infections are a major public health hazard. Consequently, it is anticipated that the growth of infectious disorders and the increasing prevalence of fungal infections like terbinafine and miconazole will propel the market for antifungal medications in North America. The market growth rate is anticipated to be driven throughout the projected period by the growing government and non-government support for antifungal diseases as well as escalating health concerns. However, more funding for research and development organizations is also probably going to help the market. 
Furthermore, the growing use of technology innovation in the region's pharmaceutical manufacturing and delivery of efficient treatment methods for a range of infectious disorders is also anticipated to support the market expansion for antifungal medications in North America. 
For instance, in March 2023, GlaxoSmithKline PLC (UK) entered into an agreement with Scynexis, Inc. (US) to commercialize and develop Brexafemme (ibrexafungerp), a first-in-class medicine to treat antifungal in the US. 
Source:(https://ir.scynexis.com/news-events/press-releases/detail/319/scynexis-reports-closing-of-exclusive-license-agreement)

For instance, in November 2022, SCYNEXIS, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, announced that the U.S. Food and Drug Administration (FDA) has approved a second indication for BREXAFEMME (ibrexafungerp tablets) for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC). 
Source:(https://ir.scynexis.com/news-events/press-releases/detail/314/scynexis-announces-fda-approval-of-second-indication-for#:~:text=BREXAFEMME%20is%20a%20novel%20oral,the%20incidence%20of%20recurrent%20VVC.)

Which Region Is Expanding at The Fastest CAGR?

The Europe region's antifungal drugs market is expected to experience the fastest growth rate with a CAGR of XX% during the forecast period. The expansion of the anti-fungal infection market in Europe is mostly driven by invasive fungal infections, which have been sharply rising in European nations over the past ten years. In the European population, invasive fungal infections are also discovered to occur in patients with hematopoietic cell transplant recipients (HCT) and hematologic malignancies. Moreover, according to Eurosurveillance, there were more and more reports of Candida auris infections in 2021 and 2022 in nations including France, Germany, Greece, Italy, the Netherlands, Spain, Belgium, and Austria. Furthermore, the Germany antifungal treatment market held the largest market share and the UK antifungal treatment market is the fastest growing market during the forecast period in the Europe region. 
For instance, in March 2023: GlaxoSmithKline plc (UK) announced an agreement with SCYNEXIS, Inc (US) to commercialize and further develop Brexafemme (ibrexafungerp) for the treatment of fungal infection.
Source:(https://www.gsk.com/en-gb/media/press-releases/gsk-and-scynexis-announce-an-exclusive-agreement-to-commercialise-and-further-develop-brexafemme-ibrexafungerp/)

For instance, in March 2023: Sanofi S.A. (France) announced that it received European commission approval for its product “Dupixent” for the children in case of severe atopic dermatitis.
Source:(https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-21-06-00-00-2630956)

The current report Scope analyzes Antifungal Drug Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

Antifungal Drug Market Analysis

Segment Performance in The Antifungal Drugs Market

Drug Class Segment Analysis

Azoles act as the prominent segment in the growth of the antifungal disease treatment market due to their efficacy in treating fungal infections. Azoles are a type of antifungal medication that stops fungus from growing by preventing ergosterol from being synthesized, which is essential for the formation of fungal cell membranes. Numerous delivery methods, the wide range of activity of azoles, and the rising incidence of fungal infections are the main drivers of this market segment's expansion. 
For instance, in 2022 as per the preliminary Centers for Disease Control and Prevention (CDC) data reported there were about 2,377 cases of Candida Auris across the U.S. Thus, a rise in fungal infections has raised global demand for azoles medications as an efficient antifungal therapy, fueling the market's expansion. 
Source:(https://www.cdc.gov/candida-auris/tracking-c-auris/index.html#:~:text=In%202022%20there%20were%202%2C377,auris.)

For instance, in August 2023, Astellas Pharma's FDA acceptance of the supplemental New Drug Application (sNDA) for CRESEMBA marks a significant industry initiative toward innovation. This acceptance focuses on treating pediatric patients with invasive aspergillosis or invasive mucormycosis. The industry's dedication to treating invasive fungal infections in children by approving azole pharmaceuticals, especially isavuconazole, may result in a rise in the market share of this category of antifungal treatments.
Source:(https://newsroom.astellas.us/2023-08-10-U-S-FDA-Accepts-Astellas-sNDA-for-CRESEMBA-R-isavuconazonium-sulfate-in-Children)
 

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Antifungal Drug Industry. Request a Free Sample PDF!

Route of Administration Segment Analysis

The Topical segment holds the largest market share in the antifungal market primarily because of its convenience, effectiveness, and ease of application. Topical antifungal treatments, such as creams, ointments, and powders, are widely used for treating superficial fungal infections like athlete's foot, ringworm, and yeast infections. Their localized application directly targets the affected area, providing quicker relief from symptoms compared to systemic medications. Growing consumer awareness of fungal diseases, a growing prevalence of fungal infections, and the market for antifungal treatments' reduced systemic adverse effects are all factors contributing to the category market growth. The route of administration market is also expanding as a result of the introduction of cutting-edge goods to satisfy the needs of patients and medical professionals.  
For instance, in March 2022, Mundipharma (UK) and Cidara Therapeutics, Inc. (US) received an approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for Rezafungin for the treatment of invasive candidiasis.
Source:(https://www.cidara.com/news/cidara-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2021-financial-results/)

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Antifungal Drug Indication Segment Analysis

Indication Segment Analysis

The Candidiasis segment is anticipated to dominate the market. The growing incidence of candidiasis is fueling the segment market's growth. Factors such as the widespread use of antibiotics, increasing incidence of immunocompromised conditions, and a growing elderly population contribute to the high occurrence of Candidiasis. Rising awareness and diagnosis are the primary drivers of the antifungal treatment market's expansion. In addition, more and more innovative treatments are being introduced to help people with the fatal fungal infection known as candidiasis. 
For instance, in March 2023, Cidara Therapeutics, Inc. (US) and Melinta Therapeutics, LLC (US) received US Food and Drug Administration approval for REZZAYO for the treatment of invasive candidiasis in adults with limited or no alternative treatment options, furthering creative flourishing opportunities for the market.
Source:(https://www.cidara.com/news/cidara-therapeutics-and-melinta-therapeutics-announce-fda-approval-of-rezzayo-rezafungin-for-injection-for-the-treatment-of-candidemia-and-invasive-candidiasis/)
 

• Dermatophytosis
• Aspergillosis
• Candidiasis
• Invasive Candidiasis
• Vulvovaginal Candidiasis
• Mouth/Throat/Esophageal Candidiasis
• Others

Antifungal Drug Pathogen Segment Analysis

Pathogen Segment Analysis

The Candida segment holds the largest market share. The market for antifungal treatments is growing at a significant rate, and this increase is mostly driven by women becoming more aware of the risks associated with factors such as the increasing incidence of immunocompromised conditions, widespread use of broad-spectrum antibiotics, and rising geriatric population contribute to the high prevalence of Candida infections. Additionally, the limited availability of effective antifungal drugs specifically targeting Candida species further drives the demand for treatments in this segment, leading to its dominant position in the antifungal market. and the rising prevalence of vulvovaginal candida. The market for antifungal treatments is growing at a significant rate, and this increase is mostly driven by women becoming more aware of the risks associated with candida infections and the rising prevalence of vulvovaginal candida.  
For instance, according to the National Institute of Health, in 2022, it was estimated that about 138 million women globally experienced recurrent vulvovaginal candida annually.
Source:(https://www.researchgate.net/figure/Global-prevalence-of-recurrent-vulvovaginal-candidiasis-per-100-000-women-in-2013_fig3_326796737#:~:text=5%20It%20has%20been%20reported,to%20158%20million%20cases%20annually.)

• Candida
• Aspergillus
• Cryptococcus
• Coccidioides Immitis
• Zygomycetes
• Trichophyton
• Others

Antifungal Drug End-User Segment Analysis

End-User Segment Analysis

The dermatology clinics segment held the largest market share. The dermatology clinics segment held the largest market due to an increase in patient visits worldwide for fungal infections of the skin, which is fueling the market's expansion. As the skin fungal infection cases are rising there is a growing need for its treatment leading to more patient visits to dermatology clinics hence fuelling the growth of the antifungal market.
For instance, in December 2023, as per Dermatology Times, multiple dermatophyte cases due to Trichophyton indotineae were reported in the United States. T indotineae is a new dermatophyte strain that is often resistant to oral terbinafine and causes extensive tinea corporis, cruris, or faciei cases. Also this year, there have been reports of onychomycosis cases due to Trichophyton rubrum resistant to oral terbinafine and oral itraconazole. Hence rising cases of dermatophytes lead to an increase in patient visits for skin fungal infections making the dermatology clinic segment dominant.
Source:(https://www.dermatologytimes.com/view/emergence-of-antifungal-resistant-dermatophyte-infections)

• Hospitals & Clinics
• Dermatology Clinics
• Others

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion